PharmaScience
http://www.pharmascience.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From PharmaScience
Old Flame Indivior Aids Addex After Being Jilted By J&J
Deal Snapshot: It has been a tough few months for the Swiss company since Johnson & Johnson pulled out of their epilepsy pact but long-time partner Indivior has run to its rescue and will advance a substance use disorder compound.
Emerging Modalities Stand Out In Recovering Korean Deal Market
While Korean biopharma companies’ out-licensing deals have remained lackluster in the past couple of years, activity around emerging modalities, led by ADCs, have been increasing in line with global trends.
Parexel Execs On Obesity, AI And Data Trends
Parexel’s chief strategy officer Kushal Gohil, clinical EVP Stephen Pyke and India head Sanjay Vyas share thoughts on possible hurdles to, and the cascading impact of obesity treatments, GenAI progress and the opportunities and challenges of real-world data in India.
Investors Hit The Alarm Bells As Indivior Issues Profit Warning
The UK group remains confident that the scale of the US opioid epidemic, driven by misuse of fentanyl, still represents a considerable opportunity but investors have reacted nervously to lower revenues coming from Sublocade.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice